checkAd
    Startseite > Aktien > Verrica Pharmaceuticals > Nachrichten
    Verrica Pharmaceuticals Aktie
    6,8700
     
    USD
    +3,31 %
    +0,2200 USD
    Letzter Kurs 26.04.24 Nasdaq
    6,8500
     
    USD
    200 STK
    Geldkurs 26.04.24
    6,8700
     
    USD
    800 STK
    Briefkurs 26.04.24
    ISIN: US92511W1080 · WKN: A2JPEV · SYM: VRCA · USA

    Neueste Nachrichten

    Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
    02.04.24 · globenewswire · Verrica Pharmaceuticals
    Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA
    26.03.24 · globenewswire · Verrica Pharmaceuticals
    VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
    09.03.24 · Business Wire (engl.) · Verrica Pharmaceuticals
    Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
    29.02.24 · globenewswire · Verrica Pharmaceuticals
    Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
    27.02.24 · globenewswire · Verrica Pharmaceuticals
    Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
    22.02.24 · globenewswire · Verrica Pharmaceuticals
    VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
    14.02.24 · Business Wire (engl.) · Verrica Pharmaceuticals
    Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
    05.02.24 · globenewswire · Verrica Pharmaceuticals
    Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH from Centers for Medicare and Medicaid Services
    29.01.24 · globenewswire · Verrica Pharmaceuticals
    Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
    05.01.24 · globenewswire · Verrica Pharmaceuticals
    Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH for the Treatment of Common Warts
    04.01.24 · globenewswire · Verrica Pharmaceuticals
    Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH
    03.01.24 · globenewswire · Verrica Pharmaceuticals